Kimio Yonesaka Selected Research

Kimio Yonesaka Research Topics

Disease

29	Neoplasms (Cancer) 01/2022 - 02/2006
24	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 11/2008
11	Colorectal Neoplasms (Colorectal Cancer) 03/2021 - 06/2011
6	Lung Neoplasms (Lung Cancer) 09/2021 - 02/2006
4	Disease Progression 09/2021 - 11/2008
4	Stomach Neoplasms (Stomach Cancer) 01/2018 - 12/2016
3	Squamous Cell Carcinoma of Head and Neck 03/2021 - 11/2008
2	Melanoma (Melanoma, Malignant) 01/2021 - 03/2018
2	Breast Neoplasms (Breast Cancer) 01/2019 - 12/2016
1	Pneumonia (Pneumonitis) 01/2022
1	Fibrosis (Cirrhosis) 01/2021
1	Hepatitis 01/2020
1	Fistula 05/2016
1	Dyspnea (Shortness of Breath) 05/2016
1	Pneumothorax 05/2016
1	Infections 12/2014
1	Deglutition Disorders (Dysphagia) 03/2014
1	Liver Diseases (Liver Disease) 03/2014
1	Exanthema (Rash) 03/2014
1	Adenocarcinoma of Lung 11/2013
1	Keratitis 08/2011
1	Hypersensitivity (Allergy) 06/2011

Drug/Important Bio-Agent (IBA)

15	ErbB Receptors (EGF Receptor)IBA 01/2022 - 11/2008
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 11/2008
10	LigandsIBA 01/2021 - 11/2008
10	Neuregulin-1 (Neuregulin 1)IBA 12/2019 - 09/2011
10	Cetuximab (Erbitux)FDA Link 09/2019 - 11/2008
5	patritumabIBA 01/2019 - 12/2014
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 11/2008
4	AfatinibIBA 01/2022 - 10/2015
4	Pharmaceutical PreparationsIBA 01/2022 - 12/2014
4	Biomarkers (Surrogate Marker)IBA 01/2018 - 12/2016
3	osimertinibIBA 01/2022 - 02/2019
3	patritumab deruxtecanIBA 01/2022 - 01/2020
3	Circulating Tumor DNAIBA 09/2021 - 01/2016
3	Immune Checkpoint InhibitorsIBA 01/2021 - 03/2018
3	Bevacizumab (Avastin)FDA Link 10/2020 - 04/2016
3	Messenger RNA (mRNA)IBA 10/2019 - 12/2016
3	Trastuzumab (Herceptin)FDA Link 01/2019 - 12/2016
3	Epidermal Growth Factor (EGF)IBA 01/2017 - 11/2008
3	AmphiregulinIBA 03/2015 - 11/2008
3	Gefitinib (Iressa)FDA Link 09/2014 - 11/2008
2	Immunoconjugates (Immunoconjugate)IBA 03/2021 - 10/2017
2	Formaldehyde (Formol)FDA Link 01/2021 - 01/2019
2	ParaffinIBA 01/2021 - 01/2019
2	Panitumumab (Vectibix)FDA Link 10/2020 - 12/2016
2	trastuzumab deruxtecanIBA 12/2019 - 10/2017
2	NivolumabIBA 03/2018 - 01/2018
2	Monoclonal AntibodiesIBA 01/2017 - 11/2013
2	histidine-rich proteinsIBA 01/2017 - 12/2014
2	Phosphotransferases (Kinase)IBA 01/2017 - 11/2013
2	SurvivinIBA 04/2007 - 02/2006
1	RNA (Ribonucleic Acid)IBA 01/2022
1	sotorasibIBA 10/2021
1	nintedanibIBA 01/2021
1	Vascular Endothelial Growth Factor DIBA 10/2020
1	AlarminsIBA 01/2020
1	exatecan (DX 8951f)IBA 01/2020
1	human ERBB2 proteinIBA 12/2019
1	Proteins (Proteins, Gene)FDA Link 12/2019
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2019
1	pertuzumabIBA 01/2019
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2019
1	S-1 plus cisplatinIBA 01/2018
1	Immune Checkpoint ProteinsIBA 01/2018
1	Indicators and Reagents (Reagents)IBA 12/2017
1	Dasatinib (BMS 354825)FDA Link 11/2017
1	Topoisomerase I InhibitorsIBA 10/2017
1	Lapatinib (GW572016)FDA Link 12/2016
1	Ado-Trastuzumab EmtansineIBA 12/2016
1	Blood Proteins (Serum Proteins)IBA 12/2016
1	Leucovorin (Folinic Acid)FDA Link 12/2016
1	Fluorouracil (Carac)FDA LinkGeneric 12/2016
1	Irinotecan (Camptosar)FDA LinkGeneric 12/2016
1	PlatinumIBA 04/2016
1	elgemtumabIBA 01/2016
1	seribantumabIBA 01/2016
1	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2015
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 03/2015
1	EGF Family of ProteinsIBA 03/2015
1	Ophthalmic Solutions (Eye Drops)IBA 08/2011
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2011
1	Platinum Compounds (Compounds, Platinum)IBA 06/2011
1	Histamine Antagonists (Antihistamines)IBA 06/2011
1	Dexamethasone (Maxidex)FDA LinkGeneric 06/2011
1	Pemetrexed (MTA)FDA Link 11/2010
1	Carboplatin (JM8)FDA LinkGeneric 11/2010
1	Sorafenib (BAY 43-9006)FDA Link 08/2009

Therapy/Procedure

22	Therapeutics 01/2022 - 11/2008
4	Drug Therapy (Chemotherapy) 01/2020 - 04/2016
3	Immunotherapy 01/2020 - 01/2018
2	Aftercare (After-Treatment) 10/2019 - 04/2016
2	Radiotherapy 05/2016 - 06/2013
1	Precision Medicine 01/2021
1	Combination Drug Therapy (Combination Chemotherapy) 01/2021
1	Plasma Exchange 01/2020
1	Re-Irradiation 05/2016
1	Gastrostomy 03/2014
1	Premedication 06/2011
1	Duration of Therapy 06/2011